1636
Image

Atty. Dkt. No. 065691-0222

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pierre Chambon *et al.*

Title: TRANSGENIC MOUSE FOR TARGETED RECOMBINATION MEDIATED BY MODIFIED CRE-ER

Appl. No.: 09/853,033

Filing Date: 05/11/2001

Examiner: Celine X. Qian

Art Unit: 1636

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

12/03/2003 TBESHAH1 00000061 09853033
01 FC:1806 180.00 OP

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding European application. A copy of the European Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language documents has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609).

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(c) in the amount of $180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date Dec. 1, 2003

By _____

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5143
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

Stephen B. Maebius
Attorney for Applicant
Registration No. 35,264

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 1, 2003

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/853,033
Filing Date	05/11/2001
First Named Inventor	Pierre Chambon
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	065691-0222

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	U.S. Patent Document Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	6,093,873	A	CHAMBON et al.	07/25/2000	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[5] (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
	A2	WO	95 00555	A	EUROP MOLECULAR BIOLOGY LAB EM	01/05/1995		
	A3	WO	94 26100	A	INST NAT SANTE RECH MED	11/24/1994		
	A4	WO	97 31108	A	GRONEMEYER HINRICH	08/28/1997		
	A5	WO	99 25851	A	SAITO IZUMU	05/27/1999		
	A6	WO	99 18222	A	ALONSO JUAN C.	04/15/1999		
	A7	WO	92 06104	A	DANA FARBER CANCER INST INC.	04/16/1992		
	A8	WO	00 49147	A	THERAGENE BIOMEDICAL LAB GMBH	08/24/2000		
	A9	WO	97 10819	A	LIGAND PHARM INC.	03/27/1997		
	A10	EP	0 698 392	A	OREAL	02/28/1996		

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 1, 2003

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	09/853,033
Filing Date	05/11/2001
First Named Inventor	Pierre Chambon
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	065691-0222

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A11	INDRA A. et al., Temporally-controlled site-specific mutagenesis in the basal layer of the epidermis: comparison of the recombinase activity of the tamoxifen-inducible Cre-ER(T) and Cre-ER(T2) recombinases, Nucleic Acids Research, Nov. 15, 1999, pp. 4324-4327, Vol. 27, No. 22, Oxford University Press, Surrey, GB	
	A12	VASIOUKHIN V. et al., The magical touch: Genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proceedings of the National Academy of Sciences of USA, July 20, 1999, pp. 8551-8556, Vol. 96, No. 15	
	A13	RAGHAVAN S. et al., Conditional ablation of betal integrin in skin. Severe defects in epidermal proliferation, basement membrane formation, and hair follicle invagination, The Journal of Cell Biology, Sept. 4, 2000, pp. 1149-1160, Vol. 150, No. 5	
	A14	FENG X. et al., Suprabasal expression of a dominant-negative RXR alpha mutant in transgenic mouse epidermis impairs regulation of gene transcription and basal keratinocyte proliferation by RAR-selective retinoids, Genes & Development, 1997, pp. 59-71, Vol. 11, No. 1	
	A15	SALTOU M. et al., Inhibition of skin development by targeted expression of a dominant-negative retinoic acid receptor, Nature, March 9, 1995, pp. 159-162, Vol. 374, MacMillan Journals Ltd., London, GB	
	A16	LI M. et al., Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis, Nature, Oct. 5, 2000, pp. 633-636, Vol. 407, No. 6804,	
	A17	KASTNER P. et al., Vitamin A deficiency and mutations of RXRalpha, RXRbeta and RARalpha lead to early differentiation of embryonic ventricular cardiomyocytes, Development, Dec. 1997, pp. 4749-4758, Vol. 124, No. 23	
	A18	SUMI-ICHINOSE C. et al., SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells, Mol. Cell Biol., Oct. 1997, pp. 5976-5986, Vol. 17, No. 10	
	A19	FEIL R. et al., Regulation of Cre recombinase activity by mutated estrogen receptor ligand-binding domains, Biochemical and Biophysical Research Communications, Aug. 28, 1997, pp. 752-757, Vol. 237, No. 3	
	A20	METZGER D. et al., Conditional site-specific recombination in mammalian cells using a ligand-dependent chimeric Cre recombinase, Proceedings of the National Academy of Sciences of USA, July 18, 1995, pp. 6991-6995, Vol. 92, No. 15, National Academy of Science, Washington, USA	
	A21	METZGER D. et al., Engineering the mouse genome by site-specific recombination, Current Opinion in Biotechnology, Oct. 1999, pp. 470-476, Vol. 10, No. 5, London, GB	
	A22	BARLOW C. et al., Targeted expression of Cre recombinase to adipose tissue of transgenic mice directs adipose-specific excision of loxP-flanked gene segments, Nucleic Acids Research, 1997, pp. 2543-2545, Vol. 25, No. 12	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date Submitted: December 1, 2003

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	09/853,033
Filing Date	05/11/2001
First Named Inventor	Pierre Chambon
Group Art Unit	1636
Examiner Name	Celine X. Qian
Attorney Docket Number	065691-0222

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
	A23	IMAI T. et al., Impaired adipogenesis and lipolysis in the mouse upon selective ablation of the retinoid X receptor alpha mediated by a tamoxifen-inducible chimeric Cre recombinase (Cre-ERT2) in adipocytes, Proceedings of the National Academy of Sciences of USA, Jan. 2, 2001, pp. 224-228, Vol. 98, No. 1, USA	
	A24	IMAI T. et al., Inducible site-specific somatic mutagenesis in mouse hepatocytes, Genesis, Feb. 2000, pp. 147-148, No. 2, Wiley-Liss, New York, NY, US	
	A25	WAN Y. et al., Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver, Mol. Cell Biol., June 2000, pp. 4436-4444, Vol. 20, No. 12	
	A26	MAHFOUDI A. et al., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists, Proceedings of the National Academy of Sciences of the United States, 1995, pp. 4206-4210, Vol. 92, No. 10	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2]See attached Kinds of U.S. Patent Documents. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.